AstraZeneca

News

AZ pulls back on Inovio immuno-oncology pact

AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech’s DNA cancer vaccines with AZ’s cancer immunotherapies.

Views & Analysis

Oncology round-up: AZ and Daiichi score key trial win with b...

AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced

Events

GIC Pharma Social - Speaker Horizontal-01 (3) 29.04

Partner Content

The Pharma Social Media Conference

Pharma Social Media

News

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm the drug’s cardiovascular safety – a good sign for the potential blockb

News

AZ and Daiichi to file new breast cancer drug after trial su...

In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new breast cancer drug – and it looks like the project is on track.

News

AstraZeneca ends leukaemia trial early after promising resul...

AstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence (acalabrutinib) early after the drug met its primary endpoint in an interim anal

AZ pulls back on Inovio immuno-oncology pact

Oncology round-up: AZ and Daiichi score key trial win with b...

The Pharma Social Media Conference

AstraZeneca shows cardiovascular safety for roxadustat

AZ and Daiichi to file new breast cancer drug after trial su...

AstraZeneca ends leukaemia trial early after promising resul...

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks